Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance. Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria – both ‘gram positive’ and…

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA